How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans
CEO Vohra Talks Strategy With Scrip
Executive Summary
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.
You may also be interested in...
Cipla Moves Into mRNA Arena With Stake In German Biotech Ethris
Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets. The Indian firm expects its next wave of growth to come from areas like biosimilars and mRNA alongside lung leadership aspirations, putting the spotlight on the broader direction of the deal.
Cipla Founding Family Pares Stake
Founding Hamied family trims holding in Cipla but the third generation currently at the helm operationally underscores that the promoter group remains invested in the front-line firm’s future.
Cipla Founding Family Pares Stake But Third Generation Affirms Continuity
Founding Hamied family trims holding in Cipla but the third generation currently at the helm operationally underscores that the promoter group remains invested in the front-line firm’s future.